Insulin resistance reduces sensitivity to cis-platinum and promotes adhesion, migration and invasion in HepG2 cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 7, 2014, Pages 3123-3128

  Li, Lin Jing ^a   Li, Guang Di ^a   Wei, Hu Lai ^a   Chen, Jing ^a   Liu, Yu Mei ^a   Li, Fei ^a   Xie, Bei ^a   Wang, Bei ^a   Li, Cai Li ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Insulin resistance; Pioglitazone hydrochloride; Proliferation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; INSULIN RECEPTOR; PIOGLITAZONE;

BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; ENERGY METABOLISM; HEPG2 CELL LINE; HUMAN; INSULIN RESISTANCE; LIVER; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GLUCOSE; GLUCOSE TRANSPORTER TYPE 2; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, INSULIN; THIAZOLIDINEDIONES;

EID: 84900843236     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.7.3123     Document Type: Article

References (23)

1. Cousin JL, Samson M, Pilch PF, Fehlmann M (1987) Internalization of insulin receptors and HLA antigens in human hepatoma cells. Biochem J, 242, 403-10.
2. Cho N, Momose Y (2008). Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem, 8, 1483-507.
3. Draznin B (2006). Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes, 55, 2392-7.
4. Donadon V, Balbi M, Perciaccante A, Casarin P, Zanette G (2009) Insulin resistance and hyperinsulinemia in patients with chronic liver disease and hepatocellular carcinoma. Clinical Medicine Insights: Endocrinology and Diabetes, 2, 25-33.
5. Gupta SP, Mittal A, Sathian B. Jha DK (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3.
6. Hu, XQ, Yuan P, Luan, RS et al (2013). Calpain-10 SNP43 and SNP19 polymorphisms and colorectal cancer: a matched case-control study. Asian Pac J Cancer Prev, 14, 6673-80.
7. Keku TO, Lund PK, Galanko J, et al (2005) Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev, 14, 2076-81.
8. Kruk J, Czerniak U (2013). Physical activity and its relation to cancer risk: updating the evidence. Asian Pac J Cancer Prev, 14, 3993-4003.
9. Liotta LA, Stetler-Stevenson WG (1991). Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 51, 5054-9.
10. Ledoux S, Yang R, Friedlander G, Laouari D (2003). Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res, 63, 7284-90.
11. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A (2007). Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol, 47, 142-56.
12. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ (2007). The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin, 57, 225-41.
13. Melin B, Cherqui G, Blivet MJ, et al (1990). Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism, 39, 1089-95.
14. Macaulay SL, Polites M, Frenkel MJ, Hewish DR, Ward CW (1995). Mutagenic structure/function analysis of the cytoplasmic cysteines of the insulin receptor. Biochem J, 306, 811-20.
15. Soliman PT, Wu D, Tortolero-Luna G, et al (2006). Association between adiponectin, insulin resistance, and endometrial cancer. Cancer, 106, 2376-81.
16. Su JL, Yang PC, Shih JY, et al (2006). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 9, 209-23.
17. Sawai H, Domae N (2011). Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun, 411, 569-73.
18. Stockert JC, Blazquez-Castro A, Canete M, Horobin RW, Villanueva A (2012). MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochem, 114, 785-96.
19. Tsujimoto M, Aozasa K, Nakajima Y, Kariya M (1984). Hepatocellular carcinoma with sarcomatous proliferation showing an unusual and wide-spread metastasis. Acta Pathol Jpn, 34, 839-45.
20. Turati F, Talamini R, Pelucchi C, et al (2013). Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer, 108, 222-8.
21. Wilcox G (2005). Insulin and insulin resistance. Clin Biochem Rev, 26, 19-39.
22. Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K (2001). Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition, 17, 590-3.
23. Yao Z, Che XC, Lu R, et al (2007). Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell. Mol Med, 13, 14-21.